Physician profile
Binyue Chang
NPI 1427497817
$2,224.54
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $397 · 2021: $1,140 · 2022: $49.16 · 2023: $171 · 2024: $16.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $367.76 | 2019-2024 | |
| Lilly USA, LLC | $300.56 | 2019-2021 | |
| Abbvie INC. | $239.95 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $225.12 | 2021-2023 | Nuplazid |
| Pfizer INC. | $155.61 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $135.76 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.89 | 2021 | |
| Avanir Pharmaceuticals, INC. | $121.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $85.02 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $83.53 | 2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $79.79 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.28 | 2019-2021 | |
| Amgen INC. | $33.56 | 2019 | |
| Amarin Pharma, INC. | $30.21 | 2019-2020 | |
| Edwards Lifesciences Corporation | $30.18 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $27.98 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.37 | 2021 | |
| Merck Sharp & Dohme LLC | $19.25 | 2020 | |
| Optinose US, INC. | $17.72 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.49 | 2020 | |
| Abbott Laboratories | $15.47 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binyue Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.